Navigation Links
GenVec Reports Second Quarter 2011 Financial Results
Date:8/9/2011

GAITHERSBURG, Md., Aug. 9, 2011 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced its financial results for the three months and six months ended June 30, 2011.  

"During the second quarter we made significant progress in key programs including our collaboration with Novartis to develop treatments for hearing loss and balance disorders," said Dr. Paul Fischer, President and Chief Executive Officer. "We enter the second half of 2011 with strong momentum and look ahead to achieving key objectives in this collaboration as well as in our vaccine programs including foot-and-mouth disease and respiratory syncytial virus."

Recent Events

  • In April, research was published describing how GenVec technology, utilizing a vector targeted to supporting cells and limited in expression to those cells, can be used to restore balance function in an animal model.
  • In May, we expanded our relationship with Merial, the animal health division of sanofi-aventis, to include the evaluation of our technology for use against swine diseases.
  • In May, we regained compliance with NASDAQ listing requirements.
  • At the Company's annual meeting in June, Adel A.F. Mahmoud, M.D., Ph.D. and Edward M. Connor, Jr., M.D. were elected to the Company's Board of Directors adding to the Board's expertise in the areas of infectious disease and vaccine development.

  • Financial Results for the Three and Six Months Ended June 30, 2011GenVec reported a net loss of $1.2 million ($0.10 per share) for the three months ended June 30, 2011 compared to a net loss of $4.2 million ($0.33 per share) in the comparable quarter of 2010. For the six months ended June 30, 2011, GenVec's net loss was $3.5 million ($0.27 per share) compared to a net loss of $8.9 million ($0.72 per share) for the six months ended June 30, 2010.  

    Revenues for the three-month an
    '/>"/>

    SOURCE GenVec, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors
    2. GenVec to Host First Quarter 2011 Earnings Call and Webcast
    3. GenVec Reports Fourth Quarter and 2010 Year-End Financial Results
    4. GenVec Forms Collaboration With World-Leading Animal Health Company
    5. GenVec Reports Third Quarter 2010 Financial Results
    6. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
    7. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
    8. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
    9. Providence Service Corporation Reports Q2 2011 Results In Line With Expectations
    10. Pharmos Corporation Reports 2011 Second Quarter Results
    11. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/2/2014)... , Oct. 1, 2014   Intarcia Therapeutics, Inc. ... its four phase 3 clinical trials for ITCA 650 ... matchstick-sized, subcutaneous osmotic mini-pump). The first trial, FREEDOM-1, was ... the efficacy and safety of ITCA 650 in patients ... ITCA 650 to be significantly superior to placebo for ...
    (Date:10/1/2014)... , Oct. 1, 2014 The ... available. Interested parties can learn about the ... Health is supporting the health care continuum ... . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... financials and the chief executive officer,s letter ...
    (Date:10/1/2014)... 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... technology used to develop and produce enzymes and ... and industrial enzymes industries, today announced the receipt ... for commercial scale production of Abengoa,s proprietary cellulase ... under Abengoa,s license agreement with Dyadic. ...
    Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
    ... Celldex also receives approval from Health Canada to ... collaboration with the National Cancer Institute, PHILLIPSBURG, ... the U.S. Food and Drug Administration (FDA) has,granted ... treatment of,EGFRvIII expressing Glioblastoma Multiforme (GBM). GBM is ...
    ... Jim Vandehei and John Harris ... The Politico, WASHINGTON, Dec. 6 , ... West Wing, 10:35 A.M. EST Q It,s an interesting time, ... on Capitol Hill right now.,But I,d love -- I mean, I,d love your overall assessment from -- ...
    Cached Medicine Technology:Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme 2Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme 3Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme 4Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme 5Interview of the Vice President 2Interview of the Vice President 3Interview of the Vice President 4Interview of the Vice President 5Interview of the Vice President 6Interview of the Vice President 7Interview of the Vice President 8Interview of the Vice President 9Interview of the Vice President 10Interview of the Vice President 11Interview of the Vice President 12Interview of the Vice President 13Interview of the Vice President 14Interview of the Vice President 15Interview of the Vice President 16
    (Date:10/2/2014)... Dennis Thompson HealthDay ... Forty-two states and the District of Columbia now have a ... respiratory illness that has been infecting children since the ... with the virus have died in recent weeks, but it,s ... played in those deaths, officials said. Health officials are ...
    (Date:10/1/2014)... today in the Journal of the American Medical ... years with moderate or severe chronic knee pain, acupuncture ... University of Melbourne randomly assigned 282 patients (50 years ... or sham or pretend laser treatment. , Treatments ... blinded to laser and sham (inactive) laser acupuncture. , ...
    (Date:10/1/2014)... that encourages people to keep their "eyes on the ... exercise. When walking, staying focused on a specific target ... and help people walk there faster, psychology researchers have ... while looking around the environment naturally, offers a new ... are less interested in exercise if physical activity seems ...
    (Date:10/1/2014)... Lifeinsurance-policy.com has released a new ... insurance prices for smokers. , Smoking will always have ... quotes is the best method to find affordable coverage. ... who need coverage. , Whole life insurance premiums ... policy. Since the coverage is permanent, the initial ...
    (Date:10/1/2014)... October 01, 2014 Join the more than ... Disorder Treatment Center’s first ever charity golf tournament to benefit ... with eating disorders who cannot afford treatment. The tournament will ... in Eureka, Mo. , The day-long event starts with ... reception and award dinner will begin at 5 p.m. and ...
    Breaking Medicine News(10 mins):Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3
    ... at PA Velodrome BREINIGSVILLE, Pa., April 26 In just ... Paradysz bested the 24-hour track record at the Valley ... a new record of 416.09 miles (669.63 kilometers) biked in ... was set in 1980. Paradysz undertook this daunting physical challenge ...
    ... A team of scientists at The Campbell Family ... Hospital and international collaborators have discovered how to trigger ... included in new clinical trials that use a patient,s ... online today in Nature Medicine (DOI: 10.1038/nm.1953), ...
    ... found they also reduced chances of erectile dysfunction , , ... statins help prevent prostate cancer and reduce the risk ... there seems to be mounting evidence that there may ... treatment or prostate cancer prevention," said Dr. Lionel L. ...
    ... Inc. and the California Family Health Council have released a statewide ... ... (PRWEB) April 26, 2009 -- ISIS, Inc., has partnered with the ... Health (CDPH), STD Control Branch, to launch a statewide text messaging ...
    ... statins may reduce inflammation in prostate tumors, possibly hindering ... in the Duke Prostate Center. , "Previous studies have ... lower incidence of advanced prostate cancer, but the mechanisms ... largely unknown," said Lionel Baez, M.D., a researcher in ...
    ... red under blue light allows physicians to more easily ... which these cancers come back, says a Mayo Clinic ... international clinical trial. , VIDEO ALERT: Additional audio and ... Lance Mynderse describing the research, are available on the ...
    Cached Medicine News:Health News:Father Breaks Cycling Record To Honor Daughter's Fight Against Lupus 2Health News:Scientists discover how to improve immune response to cancer at Princess Margaret Hospital 2Health News:Statins Guard Against Prostate Cancer 2Health News:Statins Guard Against Prostate Cancer 3Health News:Statins Guard Against Prostate Cancer 4Health News:HookUp: Sexual Health Info Text Messaging Service for California Youth Launches 2Health News:Statins may exert influence on prostate cancer growth by reducing inflammation 2Health News:Mayo Clinic researcher says improved detection of bladder tumors reduces cancer recurrence 2Health News:Mayo Clinic researcher says improved detection of bladder tumors reduces cancer recurrence 3
    5 mm tying platform. Round knurled handle with dull finish. Straight shafts. Overall length 3.9 inches....
    Curved shafts with 12 mm tying platform. Serrated handle with polished finish. Overall length 4.3 inches....
    Hartman Mosquito forceps, size 10 cm and made of Japanese S.S ....
    Hartman Mosquito forceps, straight serrated jaws, ring handle, dull finish, overall length 75 mm....
    Medicine Products: